Asymmetric Catalysis Allows Controlled Synthesis of Biologically Active Molecules
![](/46/pdcnewsitem/03/22/56/qa8VAkxmGPfQB5V.jpg)
For his outstanding research contributions to catalytic processes in synthesis of biologically active molecules, Professor Dr Nicolai Cramer is receiving the BASF Catalysis Award 2013. Professor Cramer heads the laboratory of asymmetric catalysis and synthesis at the École Polytechnique Fédérale (EPF) in Lausanne, Switzerland. The prize, worth €10,000, was presented by Dr. Andreas Kreimeyer, Member of the Board of Executive Directors of BASF SE and Research Executive Director, at the “Heidelberg Forum of Molecular Catalysis,” a symposium of international experts organized jointly by Heidelberg University, Collaborative Research Center 623 “Molecular Catalysts” and BASF SE.
“Catalysis is an important key technology for the chemical industry and is an indispensable tool for accessing new feedstocks and developing new energy efficient production processes,” said Kreimeyer. As a company with a leading international research and development platform for catalysts, BASF therefore attaches particular importance to promoting excellent young researchers in this field.
With his research group centered at EPF Lausanne, Professor Cramer is working particularly in the field of enantioselective metal-catalyzed transformations and their implementation for the synthesis of complex biologically active molecules. The Cramer lab works on the development of broadly applicable catalytic methods for the selective functionalization of relatively inert C-H and C-C bonds with different transition-metal complexes.
“We are developing precise tools for all fields that produce molecules with high reactivity and selectivity. Our methods are suited for a faster synthesis because in medical research it is also essential to produce possible active ingredients rapidly. In this way, we have synthesized and identified molecules that show an anti-HIV effect. In doing this we closely collaborate with the life sciences faculty in Lausanne,” explained the prize winner Nicolai Cramer. “But other interesting fields also exist such as material sciences in which we can provide a better approach to molecules that for example are used for organic electronics.”
The “Heidelberg Forum of Molecular Catalysis,” an international scientific symposium of top class researchers based at Heidelberg University, is being held this year for the seventh time. The event offers scientists from academia and industry the opportunity to exchange news and information about the latest research activities in molecular catalysis. Plenary presentations are being held this year not only by the prizewinner but also by Professors Stephen L. Buchwald, MIT, Cambridge, Massachusetts, Peter Chen, ETH Zürich, Switzerland, and the Nobel Prize laureate Ei-ichi Negishi, Purdue University, Indiana.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance